Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2025
Principal Event: Entry into a Material Definitive Agreement (Standby Equity Purchase Agreement) and termination of a prior agreement.
Key Financial Metrics and Transaction Details
This filing reports a capital market transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Commitment Amount: Up to $20.0 million in common stock available for sale over 36 months.
- Commitment Shares Issued: 305,960 shares of Common Stock issued immediately to the investor.
- Structuring Fee: $25,000 paid to the investor.
- Pricing Mechanism: 97% of the lowest of the three daily VWAPs during a three consecutive trading day period.
- Exchange Cap: Maximum of 2,823,244 shares (19.99% of outstanding shares) unless shareholder approval is obtained or the average sale price exceeds $0.81722 per share.
- Beneficial Ownership Limit: Investor cannot acquire shares exceeding 9.99% of outstanding voting power.
Material Changes Versus Prior Period
Termination of Prior Agreement: Effective February 12, 2025, the Company terminated its previous purchase agreement with Lincoln Park Capital Fund, LLC, which was entered into in December 2022.
New Liquidity Facility: The Company replaced the prior facility with a new Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. ("Yorkville").
Guidance, Outlook, Risks, and Contingencies
Conditions Precedent: Yorkville's obligation to purchase shares is contingent upon the filing and effectiveness of a Registration Statement with the SEC.
Regulatory Constraints: Issuances are subject to Nasdaq Stock Market rules regarding the 19.99% exchange cap and beneficial ownership limits.
Unregistered Sales: The initial Commitment Shares were issued in reliance on exemptions from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Important Facts for Investor Verification
- Verify the effectiveness of the Registration Statement required to activate the $20.0 million commitment.
- Monitor the Company's stock price relative to the $0.81722 threshold to determine if the 19.99% exchange cap can be bypassed without shareholder approval.
- Confirm the dilution impact of the 305,960 Commitment Shares already issued.
- Review the full text of the Standby Equity Purchase Agreement (Exhibit 10.1) for specific limitations on "Advances" and minimum acceptable prices.